TITLE

Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis

AUTHOR(S)
Dendukuri, Nandini; Khetani, Karim; McIsaac, Michelle; Brophy, James
PUB. DATE
May 2007
SOURCE
CMAJ: Canadian Medical Association Journal;5/8/2007, Vol. 176 Issue 10, p1429
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Testing to determine HER2 status has come into focus since the approval of trastuzumab (Herceptin) for the treatment of HER2-positive breast cancer. We compared the cost-effectiveness of various strategies used to test HER2 status, an important first step toward evaluating the overall cost-effectiveness of trastuzumab therapy. Methods: We performed a systematic review of studies that evaluated concordance between immunohistochemistry and fluorescence in situ hybridization testing to determine HER2 status. We performed a meta-analysis to estimate the distribution of immunohistochemistry scores in each category (0, 1+, 2+, 3+) and the probability of receiving a positive result of fluorescence in situ hybridization (which we assumed to be the "gold-standard" test) for each category. We calculated the accuracy and incremental cost per accurate diagnosis for each testing strategy compared with the base strategy (immunohistochemistry testing, followed by confirmation of 2+ scores by fluorescence in situ hybridization). Results: The median percentage of patients in each category of immunohistochemistry score was: 0, 36.1%; 1+, 35.5%; 2+, 12.0%; and 3+, 16.2%. The median percentage of results of fluorescence in situ hybridization that were positive in each immunohistochemistry category was: 0, 1.6%; 1+, 4.9%; 2+, 29.8%; and 3+, 92.4%. The base strategy was expected to correctly determine the HER2 status of 96% of patients with breast cancer. Confirmation of the HER2 status by fluorescence in situ hybridization in cases that received a score of 3+ reduced the percentage of false-positive results to 0% and increased the percentage of accurately determined HER2 results to 97.6%. Compared with the base strategy, this strategy was associated with a median incremental cost-effectiveness ratio of $6175 per case of accurately determined HER2 status. The strategy of performing fluorescence in situ hybridization testing in all cases of breast cancer was associated with a median incremental cost-effectiveness ratio of $8401 per case of accurately determined HER2 status. Interpretation: The strategy with the lowest cost-effectiveness ratio involved screening all newly diagnosed cases of breast cancer with immunohistochemistry and confirming scores of 2+ or 3+ with fluorescence in situ hybridization testing.
ACCESSION #
25159785

 

Related Articles

  • Spotlight on Trastuzumab in the Management of HER2-Positive Metastatic and Early-Stage Breast Cancer1. Plosker, Greg L.; Keam, Susan J. // BioDrugs;2006, Vol. 20 Issue 4, p259 

    Trastuzumab (Herceptin) is a humanized monoclonal antibody used in the treatment of breast cancer that overexpresses human epidermal growth factor receptor 2 (HER2), which is associated with clinically aggressive disease and a poor prognosis.The addition of intravenous trastuzumab to first-line...

  • Cochrane Library: Balancing trastuzumab's survival benefits and heart risks for women with breast cancer.  // Biomedical Market Newsletter;4/21/2012, Vol. 21, p1 

    The article focuses on a study, in which researchers found that trastuzumab increases the chance of prolonged life and reduces the chance of tumors reappearance after the therapy is stopped when added to the treatment offered to women who have HER2-positive breast cancer.

  • 3, 3'-diindolylmethane Enhances the Effectiveness of Herceptin against HER-2/Neu-Expressing Breast Cancer Cells. Ahmad, Aamir; Ali, Shadan; Ahmed, Alia; Ali, Azfur S.; Raz, Avraham; Sakr, Wael A.; Rahman, KM Wahidur; Ming Tan // PLoS ONE;Jan2013, Vol. 8 Issue 1, Special section p1 

    Herceptin failure is a major clinical problem in breast cancer. A subset of breast cancer patients with high HER-2/neu levels eventually experience metastatic disease progression when treated with Herceptin as a single agent. Mechanistic details of development of this aggressive disease are not...

  • Therapies Can Have Broader Utility than Screens Identify. Breindl, Anette // BioWorld Today;12/10/2012, Vol. 23 Issue 238, p1 

    The article focuses on a study published in the December 7, 2012 online issue of "Cancer Discovery" which identified a group of breast tumors that were sensitive to HER2 inhibitors. According to Ron Bose of Washington University, patients with these mutations could benefit from HER2-targerted...

  • Trastuzumab.  // Reactions Weekly;May2014, Vol. 1502 Issue 1, p37 

    An abstract of the article "Resistance to trastuzumab in HER2-positive mucinous invasive ductal breast carcinoma," by Z. Baretta and colleagues is presented.

  • OC 3: Trastuzumab in neoadjuvant treatment of HER2-positive breast cancer. Alaoui, Hasnae; Fadli, Mohammed; Ismaili, Nabil; Belbaraka, Rhizlane // Clinical Cancer Investigation Journal;2015 Supplement, Vol. 4 Issue S1, pS15 

    Trastuzumab show improved efficacy when given with chemotherapy to patients with early or lacally advanced breast cancer that has HER2 overexpression or amplification. In Morocco, trastuzumab is approved in adjuvant and metastatic cases. To confirm the efficacy of trastuzumab in the neoadjuvant...

  • Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab. Hee Jin Lee; Joo Young Kim; In Ah Park; In Hye Song; Jong Han Yu; Jin-Hee Ahn; Gyungyub Gong // American Journal of Clinical Pathology;Aug2015, Vol. 144 Issue 2, p278 

    Objectives: Tumor-infiltrating lymphocytes (TILs) have prognostic significance in breast cancer. The tertiary lymphoid structure (TLS) is related to the influx of TILs, and expression of major histocompatibility complex (MHC) I in tumor cells is necessary for the effective action of TILs....

  • ER-Poor and HER2-Positive: A Potential Subtype of Breast Cancer to Avoid Axillary Dissection in Node Positive Patients after Neoadjuvant Chemo-Trastuzumab Therapy. Li, Jian-wei; Mo, Miao; Yu, Ke-da; Chen, Can-ming; Hu, Zhen; Hou, Yi-feng; Di, Gen-hong; Wu, Jiong; Shen, Zhen-zhou; Shao, Zhi-ming; Liu, Guang-yu // PLoS ONE;Dec2014, Vol. 9 Issue 12, p1 

    Purpose: The study was to estimate the likelihood of axillary downstaging and to identify the factors predicting a pathologically node negative status after neoadjuvant chemotherapy (NAC) with or without trastuzumab in HER2-positive breast cancer. Methods: Patients with HER2-positive, stage...

  • Trastuzumab: triumphs and tribulations. Nahta, R.; Esteva, F. J. // Oncogene;5/28/2007, Vol. 26 Issue 25, p3637 

    The human epidermal growth factor receptor 2 (HER2) tyrosine kinase receptor is overexpressed in approximately 20–30% of human breast cancers, and is associated with reduced survival. Hence, numerous therapeutic strategies have been tested for their ability to target the HER2 protein. The...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics